ATE270328T1 - Transgene mäuse, die den leukämie inhibierungsfaktor exprimieren können - Google Patents

Transgene mäuse, die den leukämie inhibierungsfaktor exprimieren können

Info

Publication number
ATE270328T1
ATE270328T1 AT97921444T AT97921444T ATE270328T1 AT E270328 T1 ATE270328 T1 AT E270328T1 AT 97921444 T AT97921444 T AT 97921444T AT 97921444 T AT97921444 T AT 97921444T AT E270328 T1 ATE270328 T1 AT E270328T1
Authority
AT
Austria
Prior art keywords
transgenic mice
pituitary
inhibition factor
disorders
leukemia inhibition
Prior art date
Application number
AT97921444T
Other languages
English (en)
Inventor
Shlomo Melmed
Sadanori Akita
Carol Readhead
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Application granted granted Critical
Publication of ATE270328T1 publication Critical patent/ATE270328T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5415—Leukaemia inhibitory factor [LIF]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Environmental Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Eye Examination Apparatus (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
AT97921444T 1996-05-09 1997-04-29 Transgene mäuse, die den leukämie inhibierungsfaktor exprimieren können ATE270328T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/647,401 US5824838A (en) 1996-05-09 1996-05-09 Transgenic mouse model for pituitary disorders associated with LIF overexpression and/or GH underexpression, and its use for testing therapeutic drugs for the conditions
PCT/US1997/007177 WO1997042312A1 (en) 1996-05-09 1997-04-29 Transgenic mammals capable of expressing leukemia inhibitory factor

Publications (1)

Publication Number Publication Date
ATE270328T1 true ATE270328T1 (de) 2004-07-15

Family

ID=24596845

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97921444T ATE270328T1 (de) 1996-05-09 1997-04-29 Transgene mäuse, die den leukämie inhibierungsfaktor exprimieren können

Country Status (9)

Country Link
US (1) US5824838A (de)
EP (1) EP0914419B1 (de)
JP (1) JP2000509606A (de)
AT (1) ATE270328T1 (de)
DE (1) DE69729730T2 (de)
DK (1) DK0914419T3 (de)
ES (1) ES2219764T3 (de)
PT (1) PT914419E (de)
WO (1) WO1997042312A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP053197A0 (en) * 1997-11-26 1997-12-18 Amrad Operations Pty. Limited Compositions
AU744333B2 (en) * 1997-11-26 2002-02-21 Amrad Operations Pty. Limited Compositions of leukaemia inhibitory factor
WO2000001404A1 (en) 1998-07-06 2000-01-13 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for $i(in vitro) fertilization
US6541244B1 (en) * 1999-06-07 2003-04-01 Cedars-Sinai Medical Center Suppressor of cytokine signaling (SOCS)-3 promoter and methods for its use in genetic therapy in humans
ES2315244T3 (es) 1999-11-12 2009-04-01 Fibrogen, Inc. Gelatina recombinante en vacunas.
WO2016086197A1 (en) 2014-11-25 2016-06-02 The Brigham And Women's Hospital, Inc. Method of identifying and treating a person having a predisposition to or afflicted with a cardiometabolic disease
WO2016085876A1 (en) 2014-11-25 2016-06-02 The Broad Institute Inc. Clonal haematopoiesis
US11913166B2 (en) 2015-09-21 2024-02-27 Modern Meadow, Inc. Fiber reinforced tissue composites
KR20170096094A (ko) 2016-02-15 2017-08-23 브렌던 패트릭 퍼셀 복합체 물질을 생제작하는 방법
CA3008850A1 (en) 2017-06-29 2018-12-29 Modern Meadow, Inc. Yeast strains and methods for producing collagen
AU2018253595A1 (en) 2017-11-13 2019-05-30 Modern Meadow, Inc. Biofabricated leather articles having zonal properties
WO2020150443A1 (en) 2019-01-17 2020-07-23 Modern Meadow, Inc. Layered collagen materials and methods of making the same
US20220372511A1 (en) * 2019-06-14 2022-11-24 The Regents Of The University Of California Dna construct for targeting therapeutic molecules to diseased tissue by immune cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4736866A (en) * 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
PT87133B (pt) * 1987-04-02 1992-07-31 Amrad Corp Ltd Metodo de purificacao do factor inibidor da leucemia (lif) e de composicoes farmaceuticas contendo polipeptidos com actividade do lif
DE3854823T2 (de) * 1987-05-01 1996-05-23 Stratagene Inc Mutagenesetest durch Verwendung von nicht menschlichen Lebewesen, die Test-DNS-Sequenzen enthalten
US5175385A (en) * 1987-09-03 1992-12-29 Ohio University/Edison Animal Biotechnolgy Center Virus-resistant transgenic mice
US5175384A (en) * 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5215904A (en) * 1989-01-27 1993-06-01 Wisconsin Alumni Research Foundation Method for producing a recombinant mammal in vivo
US5175383A (en) * 1989-02-17 1992-12-29 President And Fellows Of Harvard College Animal model for benign prostatic disease
US5223610A (en) * 1990-05-18 1993-06-29 The Scripps Research Institute Cholera toxin gene regulated by growth hormone promoter

Also Published As

Publication number Publication date
US5824838A (en) 1998-10-20
EP0914419B1 (de) 2004-06-30
DE69729730D1 (de) 2004-08-05
PT914419E (pt) 2004-10-29
WO1997042312A1 (en) 1997-11-13
JP2000509606A (ja) 2000-08-02
ES2219764T3 (es) 2004-12-01
DE69729730T2 (de) 2005-07-07
EP0914419A1 (de) 1999-05-12
DK0914419T3 (da) 2004-09-06

Similar Documents

Publication Publication Date Title
DE69729730D1 (de) Transgene mäuse, die den leukämie inhibierungsfaktor exprimieren können
DK1049767T3 (da) En transgen kanin, der udtrykker et funktionelt humant lipoprotein(A)
DE60129799D1 (de) Verfahren zur steigerung des haarwuchses durch wnt polypeptid
ATE229076T1 (de) Cis elemente des ölkörperproteins als regulationische signale
PT1132403E (pt) Peptidos inibidores de tgf g beta1
ATE122205T1 (de) Fungizide zusammensetzung zur behandlung von saatgut.
ATE57690T1 (de) Pyrazolin mit insektizidischer aktivitaet.
ATE202785T1 (de) Verbindungen mit wachstumshormon-freisetzenden eigenschaften
DE69637807D1 (de) Rekombinanter lebendimpfstoff, der katzenherpesvirus typ i enthält, insbesondere für die behandlung von infektiöser bauchfellentzündung bei katzen
DE60133271D1 (de) Behandlung von knorpelerkrankungen
ATE540108T1 (de) Familie gh 61 polypeptiden
DK1011723T3 (da) 88KDA tumorgen vækstfaktor og antagonister
ATE372118T1 (de) Die verwendung von rosiglitazon zur behandlung von psychiatrischen erkrankungen.
ATE190352T1 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
ES2150901T3 (es) Antagonistas de hormonas del crecimiento.
ATE312919T1 (de) Schmerz signalisierende moleküle
ATE142431T1 (de) Tierfutter zur leistungssteigerung
ATE406438T1 (de) Menschliches homolog aus der familie der metalloproteasen
ATE550345T1 (de) Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren
DE59206628D1 (en) Expression signalpeptid-freier staphylokinasen
DE3875016D1 (de) Therapeutikum zur behandlung von aids.
ATE324906T1 (de) Verwendung von chimäres il6-il6r in huntingtonskrankheit
ATE343387T1 (de) S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen.
ATE381324T1 (de) Verwendung von mecamylamine zur behandlung von neuropsychiatrischen krankheiten die auf nicotin ansprechen
PT975630E (pt) Sulfoniloxadiazolonas e sua utilizacao como microbicidas

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0914419

Country of ref document: EP

REN Ceased due to non-payment of the annual fee